Galectin-3 as a Prognostic Biomarker in Acute Coronary Syndrome
Galectin-3, a lectin involved in inflammation and fibrosis, has emerged as an independent predictor of all-cause mortality, cardiovascular death, and heart failure following acute coronary syndrome. While troponin remains the diagnostic gold standard for ACS, galectin-3 offers complementary prognostic value by reflecting the fibrotic and inflammatory pathways that drive adverse cardiac remodeling. This review consolidates experimental and clinical evidence supporting galectin-3's role in risk stratification after acute coronary events.
The original study
Galectin-3 in acute coronary syndrome.
- Authors
- Agnello L, Bivona G, Lo Sasso B, Scazzone C, Bazan V, Bellia C, et al.
- Journal
- Clinical biochemistry
- Type
- Journal Article, Review
- PMID
- 28456545
Original abstract
Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.